Idiopathic CD4 Lymphocytopenia Clinical Trial
— Lympho-4Official title:
Analysis of Clinical and Immunological Characteristics, as Well as Pathophysiological Mechanisms in a French Cohort of Patients With Idiopathic CD4 Lymphocytopenia
| Verified date | March 2018 |
| Source | Assistance Publique - Hôpitaux de Paris |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Definition: Idiopathic CD4+ T lymphocytopenia (ICL) is an immune deficiency first described
in 1992 and characterized by the US Centers for Disease Control (CDC) as absolute CD4+
T-lymphocyte count < 300/mm3 or < 20% of total T cells on more than one cell count; no
evidence of infection with HIV-1/2 or human T-cell lymphotropic 1/2 (HTLV-1/2); and lack of a
defined immune-deficiency disease or therapy for lymphocytopenia. Epidemiologic, clinical and
immunological characteristics of the syndrome were described in 1993 and ICL is now
considered a heterogeneous syndrome not caused by an infectious agent. Patients with ICL may
show opportunistic infections such as disseminated Cryptococcus neoformans infection,
Pneumocystis jiroveci pneumonia and John Cunningham (JC) virus infection as a result of
profound cell-mediated immune-response deficiency.
Few studies have focused on the pathophysiology of ICL. CD4+ T-lymphocyte phenotyping
revealed increased CD95 expression that could be responsible for excess apoptosis leading to
lymphocytopenia. Moreover, the membrane expression of C-X-C chemokine receptor type 4 (CXCR4)
was found impaired in T lymphocytes with ICL, and CXCR4 trafficking was improved with
interleukin 2 (IL-2) treatment in some patients. Recently, mutations in nunc119, MAGT1 and
Rag were found associated with CD4+ T lymphocytopenia. In a prospective study of 39 patients,
CD8+ T lymphocytopenia (<180/mm3) and degree of CD4+ T-cell activation measured by human
leukocyte antigen DR (HLA-DR) expression was found associated with poor prognosis.
ICL is a heterogeneous disorder often associated with deficiencies in CD8+, CD19+, and/or NK
cells. Long-term prognosis may be related to initial CD4+ and NK cell deficiency.
Larger studies are needed to better identify the patients who might benefit from IL-2
therapy. This is why the investigators conduct the Lympho-4 study, in which the investigators
plan to include 200 patients with a suspected/proven diagnosis of ICL.
| Status | Completed |
| Enrollment | 47 |
| Est. completion date | September 6, 2017 |
| Est. primary completion date | September 6, 2017 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - Idiopathic CD4 lymphocytopenia defined as absolute CD4+ T-lymphocyte count < 300/mm3 or < 20% of total T cells on more than one cell count; no evidence of infection with HIV-1/2 or human T-cell lymphotropic 1/2 (HTLV-1/2); and lack of a defined immune-deficiency disease or therapy for lymphocytopenia. - Male and female patients can be included - Children and adults can be included - Hospitalized or outpatient Exclusion Criteria: - CD4+ lymphocytopenia due to another condition (HIV infection, sarcoidosis, malignant lymphoma). - Ongoing treatment possibly responsible for CD4 lymphocytopenia. - CD4+ lymphocytopenia related to primary immune deficiency - Absence of consent, of inability to obtain informed consent from the patients or the right holders. - Absence of affiliation to a social security regimen of the patient or the right holder. |
| Country | Name | City | State |
|---|---|---|---|
| France | Cochin Hospital | Paris |
| Lead Sponsor | Collaborator |
|---|---|
| Assistance Publique - Hôpitaux de Paris |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Idiopathic CD4+ T lymphocytopenia Diagnosis | Identify patients in whom the diagnosis of ICL is confirmed using an algorithm developed and applied by a multidisciplinary group of experts | 1 year | |
| Primary | Clinical, immunological and follow up characteristics of all patients | Describe and compare clinical, immunological and follow up characteristics of patients in whom the diagnosis of ICL was confirmed as compared to those in whom the diagnosis of ICL was not confirmed. | 1 year | |
| Secondary | Response to IL-2 or IL-7 treatment | Describe the response to IL-2 or IL-7 treatment | 1 year | |
| Secondary | Incident cases of ICL in first degree relatives | Evaluate incident cases of ICL in first degree relatives of patients with ICL. | 1 year | |
| Secondary | Thymic volume and correlation with CD4+ level | Quantify thymic volume in patients with ICL and correlate it with CD4+ level. | 1 year | |
| Secondary | Analysis of differentiation and activation of T and B lymphocytes | Immortalisation of cell lineages with virus Epstein Barr virus, high rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC), constitution of a biobank of frozen plasma and serum samples ; investigation of the thymic volume by performing a CT scan. Depending on clinical presentation and based on previous data obtained by our group, we will investigate the immune responses against Human papilloma virus (HPV), Cryptococcus neoformans,implication of chemokines involved in lymphocyte migration (CXCR4 and CCR7 receptors) and signalisation in response to cytokines controlling LT CD4+ homeostasis (IL-7 et IL-2). |
1 year |